NeOnc Technologies Secures Strategic PIPE Investment led by $10 Million Investment from Cinctive Capital Management

Core Viewpoint - NeOnc Technologies Holdings, Inc. has secured a private investment in public equity (PIPE) agreement, expected to generate approximately $16 million in gross proceeds, demonstrating institutional confidence in its biotech pipeline focused on central nervous system (CNS) cancers [1][2]. Group 1: Investment Details - The PIPE transaction involves the sale of up to 2,222,222 shares of common stock and five-year warrants to purchase an equal number of shares at an exercise price of $9.00, with a combined purchase price of $7.20 per share [1]. - Cinctive Capital Management LP led the investment with a commitment of $10 million, indicating strong institutional support for NeOnc's initiatives [2]. Group 2: Company Overview - NeOnc Technologies is a clinical-stage biopharmaceutical company focused on developing therapies for CNS cancers, utilizing its proprietary NEO™ drug development platform [4]. - The company’s key products, NEO100™ and NEO212™, are currently in Phase II clinical trials and have received FDA Fast-Track and Investigational New Drug (IND) status [4]. Group 3: Leadership Insights - Amir F. Heshmatpour, CEO of NeOnc, emphasized that the investment validates the company's technological approach and the potential of its clinical assets, which aim to overcome the blood-brain barrier [3]. - Rich Schimel, Co-Founder of Cinctive Capital, highlighted the innovative potential of NeOnc's delivery platforms and the firm's strategy to invest in small- to mid-cap biotech companies [3].